Egfr

Edit

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

PR Newswire 21 Mar 2026

The findings suggest that ZEGFROVY monotherapy has the potential to become the first and only chemo free, oral agent to treat newly diagnosed NSCLC patients with EGFR exon20ins ... for the treatment of relapsed or refractory NSCLC with EGFR exon20ins.

Edit

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the

Hastings Tribune 18 Mar 2026

Unique structural features of firmonertinib enhance binding ...

Edit

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel ...

Nasdaq Globe Newswire 17 Mar 2026

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc ... .

Edit

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting (Form 8-K) (ArriVent Biopharma Inc)

Public Technologies 17 Mar 2026

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting ... EGFR mutant NSCLC.

Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Nasdaq Globe Newswire 04 Mar 2026

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .

Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with

The Eagle-Tribune 04 Mar 2026

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .

Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors (Form 6-K) (HUTCHMED (China) Ltd)

Public Technologies 04 Mar 2026

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors ... - Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling -.

Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Pharmiweb 04 Mar 2026

— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — ... EGFR is highly expressed in multiple types of solid tumors and is well recognized as a driving force in tumorigenesis and disease progression.

Edit

NEOK Bio Secures FDA IND Clearance for NEOK002, a Novel EGFR/MUC1 Bispecific ADC for Treatment ...

The Galveston Daily News 02 Mar 2026

BURLINGAME, Calif.--(BUSINESS WIRE)--Mar 2, 2026-- ....

Edit

Understanding eGFR Levels and How Ayurveda Helps Maintain Kidney Health

GetNews 27 Feb 2026

One of the most important indicators of kidney function is the Estimated Glomerular Filtration Rate (eGFR). Understanding your eGFR levels can help you take timely steps to protect and support your kidney health ... Normal eGFR Range and What It Means.

Edit

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Pharmiweb 24 Feb 2026

The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.17  Among the most common driver mutations in NSCLC are alterations in EGFR, which is a ...

Edit

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (Johnson & Johnson)

Public Technologies 23 Feb 2026

The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.17Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine ...

Edit

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

PR Newswire 17 Feb 2026

... a real-world five-year OS of eight percent in the frontline setting, which is worse than patients with EGFR exon 19 deletions or L858R mutations, who have a real-world five-year OS of 19 percent.21.

Edit

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

PR Newswire 12 Feb 2026

EGFR-mutant NSCLC is driven by aberrant activation of EGFR signaling, and while EGFR-targeted therapies have dramatically improved outcomes over the past decade, acquired resistance remains inevitable for most, if not all patients.

Edit

EGFR Non Small Cell Lung Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial ...

GetNews 12 Feb 2026

The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... EGFR Non Small Cell Lung Cancer Overview.

Podcasts:

Latest News for: egfr

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel ...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting (Form 8-K) (ArriVent Biopharma Inc)

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors (Form 6-K) (HUTCHMED (China) Ltd)

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

NEOK Bio Secures FDA IND Clearance for NEOK002, a Novel EGFR/MUC1 Bispecific ADC for Treatment ...

Understanding eGFR Levels and How Ayurveda Helps Maintain Kidney Health

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (Johnson & Johnson)

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

EGFR Non Small Cell Lung Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial ...

Article Search

EXPLORE WN.com